Update to Medicare Part B step therapy program

For dates of service on or after July 1, 2024, the following drugs will be added to the Medicare Part B step therapy program:

Requested Product	Preferred Alternative Agent(s)	Special Comments
Ryzneuta (J3590)	Neulasta (J2506) Udenyca (Q5111)	N/A
Lanreotide (J1932)	Somatuline Depot (J1930)	N/A
Requested Product	**Preferred Alternative Agent(s)**	**Special Comments**
Omvoh (J3590)	Preferred adalimumab product (Humira® or biosimilar*), tofacitinib (Xeljanz® IR/XR), upadacitinib (Rinvoq®), ustekinumab (Stelara®)	Patient has had a clinical trial, inadequate response, or valid contraindication to TWO preferred agents
* Preferred Humira® biosimilar(s) are subject to change		

In-scope indications include all medically accepted indications unless otherwise noted in the table above. These step therapy requirements apply to Medicare, individual and family, small and large employer group plans as well as select Security Administrative Services groups managed by Magellan. Preferred biosimilars may differ based on line of business.

The Centers for Medicare and Medicaid Services (CMS) previously issued guidance that provides Medicare Advantage plans the option of applying step therapy for physician-administered Part B drugs in a way that lowers costs and improves the quality of care for Medicare beneficiaries.

Security Health Plan implemented step therapy requirements in 2019 and has added to the program periodically for new starts of certain targeted drugs.

Implementation will continue to be for new starts only (no use in the previous 365 days), meaning no beneficiaries currently receiving eligible step therapy drugs under Part B will have to change their drug. Step therapy prior authorization will be managed through

Security Health Plan's specialty pharmacy medication partner, Magellan. Please call 1-800-424-8243 or visit their website.